Ογ½ΆΚΣΖ΅

Skip to main content
Michael P. Teske
( out of 702 reviews )

Michael P. Teske, MD

Languages spoken: English

Clinical Locations

John A. Moran Eye Center

Salt Lake City
801-581-2352

Midvalley Health Center

Murray
801-581-2955
  • Michael P. Teske is the Director of Vitreoretinal Diseases and Surgery. Dr. Teske specializes in medical and surgical diseases of the retina and vitreous. His primary surgical interests include retinal detachment, proliferative vitreoretinopathy, diabetic retinopathy, retinopathy of prematurity, epiretinal membranes, macular holes and posterior segment trauma.

    Board Certification

    American Board of Ophthalmology
    National Board of Medical Examiners

    Patient Rating

    4.9 /5
    ( out of 702 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

    January 19, 2025
    MORAN EYE CENTER

    Highly recommend so pleasant and thoughtful I feel like I'm in the right place even though I have to travel for 5 hours he is the tops so happy I have him for my dr

    January 17, 2025
    MORAN EYE CENTER

    He. Good

    January 16, 2025
    MORAN EYE CENTER

    I met Dr. Teske for the 1st time. He was courteous and very informative. I was very impressed.

    January 04, 2025
    MORAN EYE CENTER

    Very kind, professional and pragmatic

    December 30, 2024
    UNIVERSITY OF UTAH MIDVALLEY HEALTH CENTER

    The Dr. is excellent.

    December 20, 2024
    MORAN EYE CENTER

    Nothing was rushed. Everything was explained well. I got good medical advise. I could not be more pleased.

    December 13, 2024
    MORAN EYE CENTER

    Excellent doctor.

    December 13, 2024
    UNIVERSITY OF UTAH MIDVALLEY HEALTH CENTER

    Dr Teske is a very kind and helpful doctor. My eye shots were not administered by him . It was a 'fellow ' doing the injections .

    December 12, 2024
    MORAN EYE CENTER

    He's the best. After 35 years - still on top of his game!

  • Michael P. Teske is the Director of Vitreoretinal Diseases and Surgery. Dr. Teske specializes in medical and surgical diseases of the retina and vitreous. His primary surgical interests include retinal detachment, proliferative vitreoretinopathy, diabetic retinopathy, retinopathy of prematurity, epiretinal membranes, macular holes and posterior segment trauma.

    Board Certification and Academic Information

    Academic Departments Ophthalmology & Visual Sciences -Primary
    Board Certification
    American Board of Ophthalmology
    National Board of Medical Examiners

    Education history

    Fellowship Retina/Vitreous - Wayne State Ογ½ΆΚΣΖ΅, Kresge Eye Institute Fellow
    Residency Ophthalmology - Ογ½ΆΚΣΖ΅ of Utah School of Medicine Resident
    Internship Internal Medicine - Ογ½ΆΚΣΖ΅ of Utah School of Medicine Intern
    Professional Medical Medicine - Ογ½ΆΚΣΖ΅ of California - Los Angeles M.D.
    Undergraduate Ογ½ΆΚΣΖ΅ of Notre Dame B.S.

    Selected Publications

    Journal Article

    1. Birch DG, Bernstein PS, Iannacone A, Pennesi ME, Lam BL, Heckenlively J, Csaky K, Hartnett ME, Winthrop KL, Jayasundera T, Hughbanks-Wheaton DK, Warner J, Yang P, Fish GE, Teske MP, Sklaver NK, Erker L, Chegarnov E, Smith T, Wahle A, VanVeldhuisen PC, McCormack J, Lindblad R, Bramer S, Rose S, Zilliox P, Francis PJ, Weleber RG (08/01/2018). Effect of Oral Valproic Acid vs. Placdbo for Vision Loss in Paients With Autosomal Dominant Retinitis Pigmentosa: A Randomized Phase 2 Multicenter Placebo-Controlled Clinical Trial. JAMA Ophthalmol, 136(8), 849-856.
    2. Birch DG, Bernstein PS, Iannacone A, Pennesi ME, Lam BL, Heckenlively J, Csaky K, Hartnett ME, Winthrop KL, Jayasundera T, Hughbanks-Wheaton DK, Warner J, Yang P, Fish GE, Teske MP, Sklaver NL, Erker L, Chegarnov E, Smith T, Wahle A, VanVeldhuisen PC, McCormack J, Lindblad R, Bramer S, Rose S, Zilliox P, Francis PJ, Weleber RG (2018). Effect of Oral Valproic Acid vs Placebo for Vision Loss in Patients With Autosomal Dominant Retinitis Pigmentosa: A Randomized Phase 2 Multicenter Placebo-Controlled Clinical Trial. JAMA Ophthalmol, 136(8), 849-856. ()
    3. Bell JE, Shulman JP, Swan RJ, Teske MP, Bernstein PS (2017). Intravitreal Versus Subretinal Tissue Plasminogen Activator Injection for Submacular Hemorrhage. Ophthalmic Surg Lasers Imaging Retina, 48(1), 26-32. ()